|
Operations Catalysts
Divisions sales fell by 2% to £583 million. Sales excluding the value of precious metals were 10% below last year at £342 million. The main reasons for the lower sales were adverse exchange translation and lower pass through substrate costs associated with the increasing proportion of diesel catalysts sold. Operating profit increased by 1% to £56.9 million despite the lower sales revenue. At constant exchange rates operating profit grew by 6%.
Car sales in North America were flat in the six months to 30th September 2004 at 10.2 million vehicles but domestic production was slightly down. In Western Europe sales and production were both slightly up with 8.2 million vehicles sold. Asia continues to show the most growth with a 4% increase in car sales in the main markets although the rate of growth in China slowed during the period to 12%.
Environmental
Catalysts and Technologies (ECT) achieved good growth in profits in autocatalysts with the growth coming in Asia and Europe. The division benefited from the continued growth in diesel car sales in Europe where Johnson Matthey has leading technology. Profits in the US were flat. We have increased our investment on product development for heavy duty diesel (HDD) catalysts with a number of joint programmes with original equipment manufacturers underway. This investment also benefits the next generation of light duty diesel (LDD) particulate filters. Revenue from sales of retrofit HDD products was well down on the first half of last year which had benefited from a major fitment programme in Tokyo. Despite these factors ECT’s operating profit was up on last year on a constant currency basis.
Process Catalysts and Technologies (PCT) achieved good profit growth with an encouraging first six months’ contribution from AMC, the leading supplier of Sponge Nickel™ catalysts, which was acquired in March 2004. Sales of gas processing products and syngas catalysts (used to convert natural gas or naphtha into ammonia, methanol and hydrogen) were also strong. Platinum group metal refining continues to be adversely affected by the weak palladium price and margins for that part of the division were down.
In September 2004 we concluded the acquisition of the worldwide business of Lancaster Synthesis Limited (Lancaster) from Clariant AG for £2 million. A higher price had originally been agreed for the acquisition but in July Lancaster suffered a serious fire at its UK premises which destroyed a considerable amount of stock and some of its manufacturing facilities. Lancaster’s operations remain an excellent fit with those of Johnson Matthey’s existing Research Chemicals business and its acquisition provides the opportunity to improve market share and increase operating efficiencies. An exceptional charge of £2 million has been included in operating profit to cover the cost of integrating Lancaster into Johnson Matthey’s business.
The cost of our Fuel Cells business continued at a similar rate to last year at £4.8 million. Developments in automotive fuel cells continue to be very encouraging but the market for stationary fuel cells has not grown as quickly as our customers had expected.
|
Catalysts
£ million
|
 |
Precious Metals Division’s sales increased by 23% to £1,693 million, reflecting more buoyant trading conditions for platinum group metals and higher average prices. Operating profit increased by 7% to £23.4 million despite the revised terms of the renewed contracts with Anglo Platinum and adverse exchange translation.
The average price of platinum in the first half of Johnson Matthey’s financial year rose to $837 per ounce, up 24% compared to the same period last year. This dampened purchases from jewellery manufacturers, especially in China, but growing worldwide use in the automobile and glass industries compensated. Total demand rose by less than 1% to match the record set in 2002. With supplies growing by 4%, the market was close to balance after recording significant deficits in each of the last five years.
The price of palladium showed a similar increase, up 30% to an average of $238 per ounce. Demand for palladium is expected to grow by 9% in 2004, with US auto makers using less metal from inventory and global light vehicle production rising. The most significant increase came from China where retailers, especially in the smaller cities, began stocking palladium jewellery. An 11% increase in palladium supply, driven by the expanding South African mines, prevented a more substantial recovery in the palladium price.
The division’s platinum fabrication business achieved good growth with increased demand across its product range. Sales of precision machined parts for medical device applications continue to show strong growth. The division’s gold refining businesses in North America and Hong Kong showed some modest growth in the six month period. However, the business in the UK continued to be loss making and in September 2004 the board took the decision to close the UK gold and silver bullion refinery. In 2003/04 the business made a loss of £1.6 million after metal interest and incurred a further loss of £0.6 million in the first five months of this year. Closure costs amount to £12.4 million of which £6.6 million relates to asset write offs.
|
Precious Metals
£ million
|
 |
Pharmaceutical Materials Division increased its sales by 3% to £66 million despite adverse exchange translation. Operating profit increased by 1% to £20.9 million. At constant exchange rates operating profit for the half year grew by 7%.
Macfarlan Smith was well ahead of last year with good sales of specialist opiate products, and we continue to invest in the growth of the Edinburgh facility. In the US, carboplatin sales continued to be satisfactory with the pediatric extension to the carboplatin patent extending through to October 2004. In the second half of the year the contribution from this product will fall, as generic competition develops. However, sales of other platinum based anticancer products continue to be encouraging. With ongoing technology transfers from Macfarlan Smith, West Deptford continues to make progress in manufacturing and qualifying its opiate products with new customers.
Pharm-Eco, which we have renamed Johnson Matthey Pharma Services to better reflect its market, continues to grow its small volume manufacturing segment, and has begun development of several low volume, high potency generic products. We have consolidated our prostaglandin business into its existing Cork, Ireland facility. Qualification of our prostaglandin products into new generic dosage forms continues to make good progress.
|
Pharmaceutical Materials
£ million
|
 |
Colours & Coatings Division’s sales rose by 6% to £118 million. Operating profit increased by 23% to £12.8 million. Sales of glass coating products continued to grow. Sales to the automotive sector increased, particularly sales of conductive silver paste. Demand for decorative products for other glass applications was also up.
Structural Ceramics, which sells decorative products to the tile industry, continued the recovery seen in the second half of 2003/04. In November 2003 we announced we would consider offers for parts of our Colours & Coatings Division including Structural Ceramics. The Pigments & Dispersions business was sold in September 2004 for £27 million. The board considered that the offers received for Structural Ceramics did not provide adequate value, particularly in view of the favourable outlook for the business. Consequently, the board decided that Structural Ceramics will be retained.
|
Colours & Coatings
£ million
|
 |
|